STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism
Cancer Letters · 2025-12 · 634 · 218066
DOI: 10.1016/j.canlet.2025.218066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-12. Verfasst von Yichao Bu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, STAT3 Transcription Factor, CD36 Antigens, Bile Duct Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Fudan University, Zhongshan Hospital.
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (ICC) is an aggressive bile-duct malignancy with high mortality rates, poor sensitivity to chemotherapy, and poor prognosis. Treatment options are extremely limited. Bromodomain-containing protein 9 (BRD9) has been linked to the development of various cancers, and therapies targeting BRD9 have been found to be effective. However, the role of BRD9 in ICC has not been examined, and the mechanism underlying the effects of BRD9 in cancer remain unknown. In this study, we investigated the association between BRD9 expression and ICC tumor progression, finding that high levels of BRD9 were linked to ICC tumor growth and unfavorable prognosis. In terms of the mechanism, the STAT3-BRD9-CD36 axis was found to be involved in ICC tumor growth. High BRD9 expression was found to promote CD36 expression, enhancing fatty acid metabolism in tumor cells to enable more rapid proliferation, and high BRD9 levels were influenced by elevated STAT3 expression. Treatment with the CPT1A inhibitor Etomoxir further confirmed this mechanism by blocking lipid transfer into the mitochondria and suppressing fatty acid oxidation, resulting in lipid accumulation. In addition, it was found that inhibition of BRD9 reduced ICC tumor growth and could help overcome chemoresistance. Together, the results suggest the potential of BRD9 as a therapeutic target for intrahepatic cholangiocarcinoma and highlight its role in regulating fatty acid metabolism in cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, 200032, China.
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Department of Liver Cancer Institute, Fudan University, Shanghai, 200032, China.
- Department of Liver Surgery, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, 200032, China. Electronic address: fan.jia@zs-hospital.sh.cn.
- Department of Liver Surgery, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, 200032, China. Electronic address: fangyuan1029@126.com.
- Department of Liver Surgery, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, 200032, China. Electronic address: tang.zheng@zs-hospital.sh.cn.
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- Fudan University
- Zhongshan Hospital
- National Natural Science Foundation of China
Zitieren
APA
Bu, Y., Chen, D., Li, J., Yang, R., Gao, J., Qu, W., Fu, X., Liu, W., Ding, Z., Zhou, J., Shi, Y., Fan, J., Fang, Y., & Tang, Z. (2025). STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism. Cancer Letters, 634, 218066. https://doi.org/10.1016/j.canlet.2025.218066
Vancouver
Bu Y, Chen D, Li J, Yang R, Gao J, Qu W, et al. STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism. Cancer Letters. 2025;634:218066. doi:10.1016/j.canlet.2025.218066
BibTeX
@article{Bu2025,
author = {Bu, Yichao and Chen, Diyu and Li, Jie and Yang, Rui and Gao, Jun and Qu, Weifeng and Fu, Xiutao and Liu, Weiren and Ding, Zhenbin and Zhou, Jian and Shi, Yinghong and Fan, Jia and Fang, Yuan and Tang, Zheng},
title = {STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism},
journal = {Cancer Letters},
year = {2025},
volume = {634},
pages = {218066},
doi = {10.1016/j.canlet.2025.218066}
}
EUVIMED